← Leaderboards
Ricardo A Carvalho
Targeted Therapy Technologies, Llc
$4,079,464
Attributed
$4,079,464
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.8M · FY2010–24$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,769,464 · 1
FDA$1,310,000 · 2
By mechanism
RC3$2,769,464 · 1
R01$1,310,000 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseBlood CirculationBone Marrow SuppressionCarboplatinChemotherapyChildChoroidChronicClinical TrialsDevicesDiffuseDiffusionDisease RemissionDrug FormulationsDrug KineticsEnrollmentFundingGrantHealth Care CostsHearing ImpairmentHistopathologyIntraocular RetinoblastomaLeukemiaAward
Grant awards (5)
Retinoblastoma Phase II Expanded Access Clinical Trial$650,000
R01 · FY2024 · FD · contact PI
Phase I Clinical Investigation of Episcleral Topotecan in Retinoblastoma$220,000
R01 · FY2022 · FD · contact PI
Phase I Clinical Investigation of Episcleral Topotecan in Retinoblastoma$220,000
R01 · FY2021 · FD · contact PI
Phase I Clinical Investigation of Episcleral Topotecan in Retinoblastoma$220,000
R01 · FY2019 · FD · contact PI
Episcleral Chemotherapy as Salvage Therapy for Eyes with Retinoblastoma$2,769,464
RC3 · FY2010 · CA · contact PI